姓名：丁忠仁 博士
职称：研究员
E-MAIL: dingzr@fudan.edu.cn


研究方向
1.血小板激活机制、血小板相关的动脉血栓性疾病
2.抗血小板药
重要学术贡献
1.发现血小板表达模式识别受体NOD2, NOD2激活促进血小板激活、血栓形成，与脓毒血症时血小板反应性增高有关。
2.发现血小板P2Y12受体的自发激活现象，筛选到一种强效的P2Y12受体反向激动剂，提出P2Y12受体反向激动剂具有更好的抗血小板、抗血栓作用。
3.发现糖尿病人血小板表达高水平的P2Y12受体，是病人血小板反应性增高、心血管并发症增高的原因；发现高糖-ROS-NFκB通路激活上调血小板P2Y12受体；利用糖尿病模型大鼠和糖尿病人的血小板，发现P2Y12受体反向激动剂 AR-C78511有更强的抗血小板、抗血栓作用。提出根据血小板P2Y12受体的表达水平，个体化抗血小板治疗防治糖尿病心血管并发症。
荣誉与获奖
•2017 复旦大学基础医学院“个人杰出贡献奖”
国内外学术团体任职
•2017 - 今: 中国药理学会心血管药理专业委员会委员;
•2005 - 今: 国际血栓与止血学会(ISTH)会员;
•2001 - 今: 美国血液学会(ASH)会员
受邀审稿学术刊物
2010-今 Circulation, J Thromb Haemost, Thromb Haemost
受邀学术报告 （近5年国内大会报告、国际重要会议专题报告以上）
1.2017 “抗血小板药：挑战与机遇”，第十一届海峡两岸心血管科学研讨会，奉化
2.2017 “Anti-platelet: challenge and chance”, FDSMC-KI Joint Symposium, Shanghai.
发表论文
1.Liang Hu, Lin Chang, Yan Zhang, Lili Zhai, Shenghui Zhang, Zhiyong Qi, Hongmei Yan, Yan Yan, Xinping Luo, Si Zhang, Yiping Wang, Satya P. Kunapuli, Hongying Ye, Zhongren Ding*. Platelets Express Activated P2Y12 Receptor in Patients with Diabetes. Circulation 2017; 136(9): 817 – 833 ( IF: 19.3)
2.Jianqin Ye, Lili Zhai, Shenghui Zhang, Yan Zhang, Leilei Chen, Liang Hu, Si Zhang, Zhongren Ding*. Dl-3-n-butylphthalide inhibits platelet activation via inhibition of cPLA2-mediated TXA2 synthesis and phosphodiesterase. Platelets 2015; 26(8): 736 - 44 ( IF: 3.2)
3.Si Zhang, Shenghui Zhang, Liang Hu, Lili Zhai, Ruyi Xue, Jianqin Ye, Leilei, Chen, Jozef S. Mruk, Guanjun Cheng, Satya P. Kunapuli, Zhongren Ding*. Nucleotide-Binding Oligomerization Domain 2 Receptor Is Expressed in platelets and Enhances Platelet Activation and ThrombosisIs. Circulation 2015; 131(13): 1160 - 1170 (Featured work with editorial; IF: 17.2)
4.Lei Liu, Jian Li, Yan Zhang, Shenghui Zhang, Jianqin Ye, Zhichao Wen, Jianping Ding, Satya P. Kunapuli, Xinping Luo*, Zhongren Ding*. Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory. Thromb Res 2014; 134(4): 866 - 76 (IF: 2.45)
5.Shenghui Zhang, Yan Zhang, Jian Shen, Si Zhang, Leilei Chen, Guanjun Cheng, Jozef S. Mruk, Li Zhu, Satya P. Kunapuli, Zhongren Ding*. Tumor vascular disrupting agent DMXAA inhibits platelet activation and thrombosis via inhibition of TXA2 signaling and phosphodiesterase. J Thromb Haemost 2013; 11(10): 1855 - 1866 (IF: 5.6)
6.Si Zhang, Jianqin Ye, Yan Zhang, Xiaofeng Xu, Junling Liu, Shenghui Zhang, Satya P. Kunapuli, Zhongren Ding*. P2Y12 protects platelets from apoptosis via PI3k-dependent Bak/Bax inactivation. J Thromb Haemost 2013; 11(1): 149 -160 (IF: 5.6)
7.Yan Zhang, Jianqin Ye, Liang Hu, Si Zhang, Shenghui Zhang, Yiming Li, Satya P. Kunapuli, Zhongren Ding*. Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12 receptor. J Thromb Haemost 2012; 10(10): 2149 - 2157 (IF: 6.1)
8.Change Pan，Xunbin Wei*，Jianqin Ye，Guocheng Liu, Si Zhang，Yan Zhang，Hongguang Du，Zhongren Ding*. BF066, a novel dual target antiplatelet agent without significant bleeding. PloS One 2012; 7: e40451 (IF: 3.7)
9.Liang Hu, Zhichao Fan, Hongguang Du, Ran Ni, Si Zhang, Kanhua Yin, Jianqin Ye, Yan Zhang, Xunbin Wei, Xiaohui Zhang, Peter L. Gross, Satya P. Kunapuli, Zhongren Ding*. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase. Thromb Haemost 2011; 106(6): 1203 - 14 (IF: 5.0)
10.Si Zhang, Liang Hu, Hongguang Du, Yan Guo, Yan Zhang, Haixia Niu, Jianguo Jin, Jian Zhang, Junling Liu, Xiaohui Zhang, Satya P. Kunapuli, Zhongren Ding*. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism. Thromb Haemost 2010; 104(4): 845 – 57 (cover figure; IF: 4.7)
申请或授权专利
1.授权专利
1)丁忠仁，章圣辉，张艳，张思。“肿瘤血管破坏剂DMXAA在制备抗小板、抗血栓药物中的用途” （专利号：ZL3.1），中国，发明专利。
2.申请专利
1)丁忠仁，胡亮，张艳，张思。预测II型糖尿病患者心血管并发症风险的生物标记物并根据该生物标记物进行精准化治疗的方法. 7.5. 中国，发明专利。
2)丁忠仁，陈磊磊，王建新，韩丽娜, 张思。BF061固体分散体及其制备方法和在制药中的应用。4.1。中国，发明专利。